Journal · Allergy and asthma · Updated 21 November 2026
Current Allergy and Asthma Reports
Read Current Allergy and Asthma Reports articles on DeepDyve. No university library needed.
Current Allergy and Asthma Reports offers reviews of recent research on allergic and immune-driven disease, from asthma and COPD treatments to rhinitis, chronic itch and eosinophilic esophagitis. Springer Nature publishes it. It was previously published as Current Allergy Reports. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Current Allergy and Asthma Reports at a glance
- Full title
- Current Allergy and Asthma Reports
- Former title
- Current Allergy Reports
- Abbreviation (NLM)
- Curr Allergy Asthma Rep
- Publisher
- Springer Nature
- Print ISSN
- 1529-7322
- Online ISSN (eISSN)
- 1534-6315
- Current title since
- 2001
- Subjects
- Allergy and Immunology, Pulmonary Medicine
- Access model
- Hybrid (44% free to read in 2026)
Ways to access Current Allergy and Asthma Reports
44% of the articles Current Allergy and Asthma Reports published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 44% of Current Allergy and Asthma Reports articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Current Allergy and Asthma Reports. Check its journal list and whether it offers remote access.
- DeepDyve. Read Current Allergy and Asthma Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Current Allergy and Asthma Reports’ 2025 Journal Impact Factor is 6.3, and its 5-year Impact Factor is 6.5.
6.3
Journal Impact Factor (2025)
6.5
5-year Impact Factor (2025)
13 days
Median time to first decision
Source: journal metrics on the Current Allergy and Asthma Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Current Allergy and Asthma Reports research worth reading
Published January to May 2026. Summaries describe what the authors report.
-
Standardization of Nasal Cytology: An Expert-based Delphi Consensus
In a three-round Delphi process with 100 members of the Italian Academy of Nasal Cytology, the authors reached full or partial consensus on all 30 statements, setting standards such as inferior turbinate sampling and May–Grünwald–Giemsa staining.
Macchi et al. · Current Allergy and Asthma Reports, published online February 21, 2026 · DOI 10.1007/s11882-026-01256-7
-
Biologics in Chronic Rhinosinusitis with Nasal Polyps: The Otolaryngologist’s Perspective
Armstrong and colleagues compare biologics with endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps and report that, based on cost analysis and phase 3 trial results, surgery is at least as effective in controlling symptoms at significantly less cost.
Armstrong et al. · Current Allergy and Asthma Reports, published online January 10, 2026 · DOI 10.1007/s11882-025-01243-4
-
Chronic Rhinosinusitis Optimisation of Nasal Outcomes and Scores (CHRONOS): An Italian Delphi Consensus on Long-Term Management with Biologics
De Corso and colleagues present the Italian CHRONOS Delphi consensus on long-term biologic therapy for severe chronic rhinosinusitis with nasal polyps, advising that dose-spacing may be appropriate in stable patients and that biologics may be considered before surgery only in selected complex cases.
De Corso et al. · Current Allergy and Asthma Reports, published online January 9, 2026 · DOI 10.1007/s11882-025-01246-1
-
Inverted Sinonasal Papilloma: Pheno-endotyping and Predictive Markers of Recurrence and Malignancy – A Systematic Review
In a systematic review of inverted sinonasal papilloma, Aguilera and colleagues report that HPV-18, EGFR exon 20 mutations, p53 alterations and p16 loss have been most consistently linked to recurrence and malignant progression, though markers vary considerably across studies.
Aguilera et al. · Current Allergy and Asthma Reports, published online January 28, 2026 · DOI 10.1007/s11882-025-01247-0
-
The Emerging Role of Ly6G⁺Nur77⁺ Lung Macrophages in Type-2 Allergic Inflammation: A Comprehensive Review on Asthma Pathogenesis
Mehmood and colleagues review a lung macrophage population expressing Ly6G and Nur77 that appears to play a dual role in asthma, initiating allergen-driven Th2 responses while also helping control inflammation, and discuss it as a potential target in severe and steroid-resistant asthma.
Mehmood et al. · Current Allergy and Asthma Reports, published online May 7, 2026 · DOI 10.1007/s11882-026-01274-5
See every Current Allergy and Asthma Reports article on DeepDyve
Related journals
Questions about Current Allergy and Asthma Reports
How can I read Current Allergy and Asthma Reports articles without a subscription?
44% of Current Allergy and Asthma Reports articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Allergy and Asthma Reports articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Current Allergy and Asthma Reports?
Current Allergy and Asthma Reports’ NLM (PubMed) abbreviation is Curr Allergy Asthma Rep.
What is the ISSN of Current Allergy and Asthma Reports?
The print ISSN is 1529-7322 and the online ISSN is 1534-6315.
What is the impact factor of Current Allergy and Asthma Reports?
Current Allergy and Asthma Reports’ Journal Impact Factor is 6.3 (2025), and its 5-year Impact Factor is 6.5, according to Springer Nature’s published metrics.
Is Current Allergy and Asthma Reports open access?
Current Allergy and Asthma Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 28 of 63 Current Allergy and Asthma Reports articles (44%) carry a Creative Commons license, per Crossref.
Current Allergy and Asthma Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Current Allergy and Asthma Reports today
One month free, then less than $2 a day. Current Allergy and Asthma Reports, plus millions of articles from thousands of journals.





